- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Damora Therapeutics, Inc.: Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 23.03. | Damora Therapeutics: Aktie legt nach Ernennung neuer CEO deutlich zu | 4 | Investing.com Deutsch | ||
| 23.03. | Damora Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.03. | Damora Therapeutics appoints Jennifer Jarrett as CEO | 1 | Seeking Alpha | ||
| DAMORA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.03. | Damora names Jennifer Jarrett CEO, adds two board members | 1 | Investing.com | ||
| 23.03. | Damora Therapeutics, Inc.: Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors | 630 | GlobeNewswire (Europe) | -- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter... ► Artikel lesen | |
| 20.03. | Leerink cuts Damora Therapeutics stock price target to $55 on timing | 2 | Investing.com | ||
| 20.03. | Damora Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 20.03. | Leerink senkt Kursziel für Damora Therapeutics wegen Zeitplan-Anpassungen | 1 | Investing.com Deutsch | ||
| 19.03. | Damora Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.03. | Galecto, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.03. | Galecto rebrands as Damora Therapeutics, begins Nasdaq trading | 3 | Investing.com | ||
| 09.03. | Galecto, Inc.: Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders | 243 | GlobeNewswire (Europe) | -- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis... ► Artikel lesen | |
| 04.03. | Galecto, Inc.: Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 17.02. | UBS initiates Galecto stock with buy rating on blood disorder drug | 11 | Investing.com | ||
| 12.02. | Galecto, Inc.: Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million | 1 | GlobeNewswire (USA) | ||
| 11.02. | Galecto shares fall after $275 million equity raise at discount | 1 | Investing.com | ||
| 11.02. | Galecto prices $275M stock offering | 3 | Seeking Alpha | ||
| 11.02. | Galecto prices $275 million public offering at $19 per share | 1 | Investing.com | ||
| 11.02. | Galecto, Inc.: Galecto Announces Pricing of $275 Million Underwritten Public Offering | 4 | GlobeNewswire (USA) |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,20 | +0,13 % | BioNTech überrascht: Krebsdaten geben Hoffnung! | BioNTech treibt den strategischen Wandel hin zu einem Onkologie-Unternehmen voran und erzielt dabei erste vielversprechende klinische Fortschritte, insbesondere im Bereich Lungenkrebs. Gleichzeitig... ► Artikel lesen | |
| EVOTEC | 4,503 | +1,03 % | Evotec vor Kurssprung? Analysten und Charttechnik signalisieren Aufwärtspotenzial! | ||
| AMGEN | 301,50 | -0,07 % | Amgen: Repatha Cuts Risk Of First Major Cardiovascular Events By 31% In High-risk Patients Without Known Significant Atherosclerosis | Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention
VESALIUS-CV Subgroup Findings Reinforce Benefit... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,110 | -0,17 % | Where Will Viking Therapeutics Stock Be in 10 Years? | ||
| DEFENCE THERAPEUTICS | 0,337 | +1,81 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Warrant Terms Amendment | Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,412 | -0,96 % | Megatrend Nanotechnologie rückt in den Fokus der Kapitalmärkte | ||
| ABIVAX | 101,20 | -0,39 % | EQS-News: ABIVAX: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01.04.2026 / 22:05 CET/CEST
The... ► Artikel lesen | |
| IBIO | 1,590 | -7,56 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 53,20 | +0,49 % | S&P Dow Jones Indices: Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 | NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:
S&P MidCap 400... ► Artikel lesen | |
| GALAPAGOS NV | 25,660 | -0,93 % | Galapagos Enters Framework Agreement With Gilead In Connection With Ouro Deal | FOSTER CITY (dpa-AFX) - Galapagos (GLPG, GLPG.AS) has entered into a binding agreement with Gilead Sciences (GILD) in connection with Gilead's agreement to acquire all of the outstanding equity... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,550 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates | On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 12,770 | -0,31 % | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics... ► Artikel lesen | |
| CYTOKINETICS | 57,00 | -1,72 % | Cytokinetics: Evercore ISI bestätigt "Outperform"-Rating im Vorfeld entscheidender Studiendaten | ||
| CYTOMX THERAPEUTICS | 3,742 | -5,07 % | CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress | ||
| VOYAGER THERAPEUTICS | 3,370 | -0,82 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen |
DAMORA THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,12 % bei einem Aktienkurs von 25,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAMORA THERAPEUTICS INC finden Sie auf Wallstreet Online.